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The majority of Congenital Disorders of 
Glycosylation (CDG) are caused by defects of 
dolichol (Dol)-linked oligosaccharide assembly, 
which lead to under-occupancy of N-
glycosylation sites. Most mutations encountered 
in CDG are hypomorphic, thus leaving residual 
activity to the affected biosynthetic enzymes. We 
hypothesized that increased cellular levels of 
Dol-linked substrates might compensate for the 
low biosynthetic activity and thereby improve 
the output of protein N-glycosylation in CDG. 
To this end, we have investigated the potential of 
the squalene synthase inhibitor zaragozic acid to 
redirect the flow of the poly-isoprene pathway 
towards Dol by lowering cholesterol 
biosynthesis. The addition of zaragozic acid to 
CDG fibroblasts with a Dol-P-Man synthase 
defect led to the formation of longer Dol-P 
species and to increased Dol-P-Man levels. This 
treatment was shown to decrease the pathologic 
accumulation of incomplete Dol-PP-
GlcNAc2Man5 in Dol-P-Man synthase deficient 
fibroblasts. Zaragozic acid treatment also 
decreased the amount of truncated protein N-
linked oligosaccharides in these CDG 
fibroblasts. The increased cellular levels of Dol-
P-Man and possibly the decreased cholesterol 
levels in zaragozic acid-treated cells also led to 
increased availability of the glycosylphospha-
tidylinositol-anchor as shown by the elevated 
cell surface expression of the CD59 protein. The 
present study shows that manipulation of the 
cellular Dol pool, as achieved by zaragozic acid 
addition, may represent a valuable approach 
aimed at improving N-linked glycosylation in 
CDG cells. 
 
Congenital Disorders of Glycosylation (CDG)a are 
a group of inherited defects of protein glycosylation 
(1). Mutations in genes encoding either proteins 
involved in biosynthesis of lipid-linked 
oligosaccharide (LLO) required for N-
glycosylation (2) or proteins involved in glycan 
processing (3,4) or transport of N-glycoproteins (5) 
form the molecular basis of CDG. The majority of 
CDG encompass disorders affecting the assembly 
of the LLO precursor dolichol-pyrophosphate (Dol-
PP)-GlcNAc2Man9Glc3, which leads to under-
occupancy of N-glycosylation sites (6). The 
stepwise biosynthesis of the LLO precursor begins 
at the cytosolic side of the endoplasmic reticulum 
(ER) membrane by transfer of GlcNAc-P to 
dolichol-P (Dol-P) and completes at the luminal 
side of the ER membrane. Dol-P does not only 
serve as carrier of maturing LLO, but also as lipid 
component of Dol-P-Man and Dol-P-Glc, both 
donor substrates for luminally acting mannosyl- 
and glucosyltransferases (7). 
The symptoms associated to CDG are principally of 
neurologic nature, such as psychomotor retardation, 
ataxia and hypotonia but also include hormonal 
alterations and coagulopathies (8). The clinical 
severity of CDG mainly depends on the degree of 
N-glycosylation site under-occupancy (9), which 
itself depends on the available pool of complete 
LLO Dol-PP-GlcNAc2Man9Glc3. To date, only two 
forms of CDG can be successfully treated by oral 
carbohydrate supplementation. The glycosylation 
defects resulting from deficiency of Man-P 
isomerase (MPI) can be corrected by Man 
supplementation (10,11), whereas Fuc uptake has 
been shown to rescue the deficiency of GDP-Fuc 
transport (12). Considering the involvement of Dol 
throughout the LLO biosynthetic pathway, we 
made the hypothesis that increased cellular levels 
of Dol and Dol-P based substrates may increase the 
formation of Dol-PP-GlcNAc2Man9Glc3 in CDG. 
Dol biosynthesis follows the sterol pathway up to 
the formation of the C15-intermediate farnesyl-PP 
(13) (Fig. 1A). Instead of squalene formation by 
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head to head assembly of two farnesyl-PP 
molecules (14), the consecutive condensation of 
isopentenyl-PP units leads to the diverging 
synthesis of polyprenyl-PP, a pre-stage of Dol-P. 
The enzyme squalene synthase catalyzes the first 
reaction leading exclusively to the formation of 
sterol compounds, such as cholesterol and steroid 
hormones (Fig. 1A). Inhibition of squalene 
synthase, for example by zaragozic acid A (ZGA), 
leads to the stimulation of prior diverging 
pathways, and hence to increased formation of Dol 
and Dol-P (15). ZGA, also known as squalestatin I, 
was discovered by screening metabolites of 
filamentous fungi for cholesterol lowering activity 
(16). Detailed analysis disclosed that ZGA acts as a 
competitive inhibitor of the squalene synthase by 
mimicking the farnesyl-PP substrate or the stable 
intermediate presqualene-PP with its bicyclic, 
highly acidic core (Fig. 1B). In contrast to statins 
acting on common steps of both Dol and 
cholesterol biosynthesis, such as the 3-hydroxy-3-
methyl-glutaryl coenzyme A (HMG-CoA) 
reductase inhibitors pravastatin (17), lovastatin (18) 
or rosuvastatin (19), ZGA does not negatively 
affect the diverging pathways generating Dol, 
ubiquinone or prenylated proteins (Fig. 1A). In the 
present study, we have investigated the ability of 
the squalene synthase inhibitor to increase Dol 
biosynthesis and thereby the output of N-
glycosylation in CDG fibroblasts. 
 
EXPERIMENTAL PROCEDURES 
Materials - ZGA was a gift from Merck & Co., Inc. 
(Rahway, NJ). The C80-polyprenyl-P standards 
were purchased from Larodan Fine Chemicals 
(Sweden), and broad range mammalian Dol-P 
standards were from Sigma-Aldrich (Switzerland). 
Acetonitrile (Scharlau, Spain), dichloromethane 
(Sigma-Aldrich) and water (Sigma-Aldrich) were 
of HPLC grade, other chemicals were of analytical 
grade. 
Cholesterol analysis – Human primary skin 
fibroblasts (4 x 107 cells) cultured in DMEM 
(Sigma-Aldrich) with 10% fetal calf serum 
(Bioconcept, Switzerland) at 37°C were treated for 
72 h with either 100 μM ZGA or DMSO alone as 
negative control. Cells were harvested by 
trypsinization, washed in PBS and centrifuged at 
1000 x g for 5 min. To the cell pellet 1 ml of 4 % 
(w/v) KOH in 90 % ethanol was added. After 
vortexing, the solution was incubated for 10 min in 
a ultrasonic bath and transferred to a glass tube. 
After addition of 80 l of internal standard (0.1 
mg/ml epicoprostanol (Sigma-Aldrich) in pyridine), 
the solution was saponified for 60 min at 60°C, 
mixed with 1 ml of water and extracted three times 
with 2 ml heptane. The pooled heptane extracts 
were dried under nitrogen and derivatized with 75 
L BSTFA (Machery-Nagel, Oensingen, 
Switerzland) in 75 l pyridine at 60°C for 60 min. 
For GC/MS analysis, the derivative mixture was 
diluted 5-fold with heptane and 1 l was injected 
(injector temperature: 280°C; splitless injection). A 
Restek RTX-1MS (BGB Analytik AG, Böckten, 
Switzerland) column (15 m, ID = 0.25 mm) was 
used for chromatographic separation of the sterols. 
The carrier gas was helium at a constant flow of 1.5 
mL/min. After a dwell time of 3 min at 90°C, the 
oven temperature was raised to 200°C at 20°C/min, 
then to 260°C at 1.5°C/min, and finally held at 
260°C for 10 min. Mass spectrometry was 
performed on a Finnigan PolarisQ ion trap mass 
spectrometer. Mass spectra were acquired in the 
mass range of m/z = 50 - 550. 
Dol-P analysis – Fibroblasts (4 x 107 cells) were 
harvested and centrifuged at 1000 x g for 5 min. 
Cell pellets were dissolved in 12 ml of 
water/methanol (1:1). Prior to alkaline hydrolysis 
(20), 15 μg of C80-polyprenyl-P standards were 
added. The extracted Dol and Dol-P were purified 
on a C18 Sep Pak column (Waters, USA) and 
subsequently separated on a Silica Sep Pak column 
(Waters) (21). The Dol-P were dimethylated using 
diazomethane generated in an Aldrich 
diazomethane generator system (Sigma-Aldrich) 
according to the manufacturer’s instructions. The 
resulting Dol-P-Me2 were selectively demethylated 
by overnight incubation in tert-butylamine (Sigma-
Aldrich) at 70°C (22). Monomethylated Dol-P 
samples were dissolved in a saturated solution of 9-
anthryldiazomethane (Sigma-Aldrich) in 
diethylether and incubated for 6 h on ice in the 
dark. Anthracene labeled Dol-P were separated 
from non-reacted labeling agent by organic 
extraction (22). The purified products were 
dissolved in acetonitrile/dichloromethane (3:2) and 
subjected to HPLC on an Inertsil ODS-3 column (5 
μm, 4.6 x 250 mm; GL Sciences Inc., Japan) 
equipped with a precolumn. Isocratic elution in 
acetonitrile/dichloromethane (3:2) and 0.01% 
diethylamine (Sigma-Aldrich) was performed at a 
flow rate of 1 ml/min (22). Fluorescent labeled 
Dol-P were detected by excitation at 365 nm and 
emission at 412 nm. Defined amounts of internal 
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standard C80-polyprenyl-P were used for 
quantification. 
Determination of Dol-P-Man - Approximately 4 x 
107 fibroblasts were grown for 72 h in DMEM 
containing low Glc (5 mM; Sigma-Aldrich), 
supplemented with 2% fetal calf serum and 100 μM 
ZGA or DMSO as negative control. Low Glc 
medium was utilized to achieve improved Man 
incorporation (23). Cellular Dol-P-Man was 
metabolically labeled, extracted and purified 
according to the protocol of Körner and co-workers 
(23). Briefly, the fibroblasts were labeled by 
incubation in DMEM containing 0.5 mM Glc and 
125 µCi [3H]-Man (Hartmann Analytic, Germany) 
for 30 min. Dol-P-Man and short LLO were 
extracted once with chloroform/methanol (2:1) and 
twice with chloroform/methanol (3:2). The 
combined organic phases were dried and washed. 
Thin-layer chromatography on Silica gel 60 plates 
was performed in chloroform/methanol/water 
(65:25:4). The plates were analyzed by radiography 
after signal enhancement with an EN3HANCE 
spray (PerkinElmer, USA) and the area containing 
Dol-P-Man were scraped and counted in a TRI–
CARB 2900 TR liquid scintillation analyzer 
(Packard, USA). 
CD59 flow cytometry - Fibroblasts (2 x 105 cells) 
were harvested by trypsinization, washed once in 
PBS containing 2% fetal calf serum and incubated 
with a FITC conjugated mouse anti-human CD59 
antibody (BD Pharmingen, USA) diluted 1:100 in 
PBS containing 2% fetal calf serum for 20 min on 
ice (24). Fibroblasts were washed and analyzed on 
a BD FACSCanto II flow cytometer (BD 
Biosciences, USA) equipped with BD FACSDiva 
software (BD Biosciences). 
LLO and N-linked oligosaccharide (NLO) 
analysis - The LLO profiles of 1.5 x 107 fibroblasts 
treated for 72 h with either 100 μM ZGA or DMSO 
were analyzed as described (25). The cells were 
starved for 45 min in fetal calf serum- and Glc-free 
DMEM (Invitrogen) and metabolically labeled for 
60 min by addition of 150 μCi [3H]-Man. LLO 
were extracted from cell pellets and 
oligosaccharides were released by mild acid 
hydrolysis in 0.1 N HCl. Glycoproteins recovered 
from the LLO extraction were denatured and NLO 
were released by overnight incubation with 
PNGaseF endoglycosidase (New England BioLabs, 
USA) (26). Oligosaccharides were purified by ion-
exchange chromatography on AG1-X2 and 
AG50W-X8 resins (Bio-Rad, USA) and by 
hydrophobic chromatography on Supelclean ENVI-
Carb 120/400 beads (Supelco, USA) and C18 Sep 
Pak columns and subjected to HPLC analysis. 
Statistics - Results were expressed as mean ± SEM. 
The one-way ANOVA test with Bonferroni’s 
multiple comparison post-test was applied to 
confirm differences between groups. Significance 
was accepted for p<0.05. 
 
RESULTS 
The toxicity of ZGA was first determined by 
incubating human primary skin fibroblasts for ten 
days with increasing concentrations from 10 to 500 
µM. ZGA was tolerated by fibroblasts up to a 
concentration of 125 µM. Above that concentra-
tion, the rate of cell proliferation slowed down and 
cell morphology was altered (data not shown). The 
addition of 100 µM ZGA to healthy control and 
CDG fibroblasts led to a moderate decrease of 
cellular cholesterol levels by 15% and 30%, 
respectively (Fig. 2). 
The effect of ZGA on glycosylation was deter-
mined by measuring cellular levels of Dol-P, Dol-
P-Man, a glycosylphosphatidylinositol (GPI)-
anchored model protein, LLO and NLO. The 
impact of ZGA on Dol-P levels was first addressed 
on healthy control fibroblasts. After labeling with 
the fluorochrome 9-anthryldiazomethane, Dol-P 
levels were quantitated after HPLC separation (21). 
The resulting fluorescent HPLC profiles of 
untreated cells (Fig. 3A) and of cells treated with 
100 μM ZGA for 72 h (Fig. 3B) were compared. 
The pattern of Dol-P species changed upon ZGA 
treatment, where the amount of longer C100- and 
C105-Dol-P increased in ZGA treated fibroblasts 
(Fig. 3C). 
To address the effect of ZGA on various 
parameters of LLO biosynthesis in CDG, we chose 
fibroblasts with a deficiency of Dol-P-Man 
synthase-1 (DPM1) (24), which present low Dol-P-
Man levels, an accumulation of the LLO Dol-PP-
GlcNAc2Man5 and the corresponding 
GlcNAc2Man5 glycan structure on glycoproteins. 
Dol-P-Man production was measured after labeling 
cells with [3H]-Man. The [3H]-Dol-P-Man pool 
determined in DPM1-deficient fibroblasts reached 
65% of the levels measured in healthy control cells 
(Fig. 4). When DPM1-deficient fibroblasts were 
treated with 100 µM ZGA	for 72 h, the [3H]-Dol-P-
Man levels increased by reaching 120% of normal 
values. Similarly, when healthy control fibroblasts 
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were incubated with 100 µM ZGA, the levels of 
[3H]-Dol-P-Man increased by 150% (Fig. 4).  
DPM1 deficiency leads to reduced cell surface 
expression of GPI-anchored proteins, since Dol-P-
Man is required for the assembly of the GPI anchor 
(27). Accordingly, low levels of the GPI-anchored 
protein CD59 have been detected on the cell 
surface of DPM1-deficient fibroblasts (24). The 
addition of ZGA led to increased expression of 
CD59 in healthy control (Fig. 5A) and DPM1-
deficient fibroblasts (Fig. 5B), as monitored by 
flow cytometry. When DPM1-deficient fibroblasts 
were treated with 100 µM ZGA for 72 h, the cell 
surface levels of CD59 returned to the levels 
observed in untreated control fibroblasts (Fig. 5C). 
A time course experiment showed that the ZGA 
effect was maximal by 72 h of treatment, whereas 
longer periods did not increase CD59 expression 
further (Fig. 5C). The effect on CD59 expression 
was also maximal when applying ZGA at 100 μM, 
but changes were already visible with lower ZGA 
concentrations (Fig. 5D). 
The biosynthesis of the LLO Dol-PP-
GlcNAc2Man9Glc3 requires Dol as carrier of the 
growing oligosaccharide and as donor substrate for 
Dol-P-Man and Dol-P-Glc (7). In normal cells, 
only the complete LLO Dol-PP-GlcNAc2Man9Glc3 
can be detected (Fig. 6A). DPM1 deficiency leads 
to the accumulation of the intermediate LLO Dol-
PP-GlcNAc2Man5 (Fig. 6C) (24,28). The amount of 
this incomplete LLO could be reduced by treatment 
of DPM1-deficient fibroblasts with 100 µM ZGA. 
The ratio of the abnormal Dol-PP-GlcNAc2Man5 
peak to the mature Dol-PP-GlcNAc2Man9Glc3 peak 
was decreased from 54% to 17% under ZGA 
supplementation (Fig. 6D). By comparison, the 
addition of 100 µM ZGA to control fibroblasts did 
not influence the quality of the LLO profile (Fig. 
6B). 
After transfer from LLO to proteins, the NLO 
GlcNAc2Man9Glc3 is trimmed by glucosidases and 
mannosidases in the ER (29). The analysis of NLO 
after [3H]-Man labeling of control fibroblasts 
showed, as expected, GlcNAc2Man8, GlcNAc2Man9 
and GlcNAc2Man9Glc1 as main oligosaccharide 
structures (Fig. 7A). In DPM1-deficient fibroblasts, 
several intermediary oligosaccharide structures 
ranging from GlcNAc2Man4 to GlcNAc2Man7 were 
found, whereas the normal oligosaccharides 
GlcNAc2Man8, GlcNAc2Man9 and 
GlcNAc2Man9Glc1 were under-represented (Fig. 
7C). While ZGA treatment did not affect the NLO 
profile of control fibroblasts (Fig. 7B), it decreased 
the occurrence of abnormal N-linked glycans 
GlcNAc2Man4 to GlcNAc2Man7 and increased the 
amounts of the normal NLO GlcNAc2Man8, 
GlcNAc2Man9 and GlcNAc2Man9Glc1 in DPM1-
deficient fibroblasts (Fig. 7D). In these cells, the 
ratio of the pathologic GlcNAc2Man5 peak to the 
normal GlcNAc2Man9 peak was 422% and this 
ratio was decreased to 143% after addition of ZGA 
(Fig. 7D). This normalization of the NLO profile 
demonstrated the beneficial effect of ZGA 
treatment on N-glycosylation. 
Taken together, the present study showed that 
treatment of human CDG fibroblasts with the 
squalene synthase inhibitor ZGA stimulated Dol-P 
biosynthesis and thereby improved the level of N-
glycosylation in conditions of limited substrate 
availability as encountered in DPM1-deficiency. In 
addition, the supplementation with ZGA resulted in 
the normalization of the expression of the GPI-
anchored protein CD59 on DPM1-deficient 
fibroblasts. 
 
DISCUSSION 
Successful treatment of biosynthetic CDG is 
restricted so far to oral administration of Man to 
Man-P isomerase deficient (MPI-CDG) patients 
(10,11). The applied Man could be phosphorylated 
by hexokinase and allows functional bypassing of 
the defective isomerization of fructose-6-P to Man-
6-P. In the group of Golgi-associated CDG, a 
deficiency of the Golgi GDP-Fuc transporter 
(SLC35C1-CDG or leukocyte adhesion deficiency 
type II) (30) could also be treated by simple 
supplementation of a monosaccharide. Oral Fuc 
administration induced the expression of 
fucosylated glycoproteins and within short terms, 
the clinical symptoms of a SLC35C1-CDG patient 
could be relieved (12). Moreover, a few elementary 
attempts have been conducted to treat 
phosphomannomutase-2 deficiency (PMM2-CDG), 
which forms by far the largest CDG subtype (31). 
Mutations in the PMM2 gene lead to disrupted 
conversion of Man-6-P to Man-1-P, which acts as 
precursor of GDP-Man (32). However, Man-1-P is 
neither able to diffuse through biological 
membranes nor does a transport system exist. Thus, 
it needs chemical modification prior to direct 
administration to overcome this obstacle (33-35). 
Membrane permeable Man-1-P analogues were 
successful in restoring LLO biosynthesis in CDG 
patient cells, but such prodrugs were toxic, very 
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unstable and had to be applied in high 
concentrations (33). 
Shang and Lehrman discovered a metformin-
stimulated Man specific transport activity in human 
fibroblasts (36). The resulting increased Man 
uptake was shown to be able to correct artificially 
induced defects in LLO biosynthesis and protein N-
glycosylation in control and PMM2-CDG 
fibroblasts. However, the observation that the 
clinical phenotype of PMM2 deficiency could not 
be treated with dietary Man, which was actually 
effective in cellular models (31), renders a 
therapeutic administration of metformin 
questionable. 
Our approach to increase Dol-P biosynthesis by 
inhibition of the squalene synthase offers a 
therapeutic perspective for inherited biosynthetic 
N-glycosylation defects featuring residual 
enzymatic activity. Conveniently, ZGA is well 
tolerated in animal experiments (37,38) compared 
to classical statins, which interfere with various 
isoprenoid-based biosynthesis pathways and are 
associated to adverse effects (39). We could show 
that ZGA decreased cellular cholesterol levels, 
although only by 15-30%, indicating that 
membrane properties were likely unaltered due to 
this treatment. However, we cannot exclude an 
effect of the lowered cholesterol levels on the 
formation of glycolipid rafts, in which GPI-
anchored proteins partition. Accordingly, the 
increased expression of the GPI-anchored protein 
CD59 observed in ZGA-treated cells could be 
caused by increased Dol-P availability and altered 
raft distribution. By contrast, the positive effect of 
ZGA supplementation on Dol-P-Man levels and 
LLO patterns in DPM1-CDG fibroblasts are 
unlikely to be related to decreased cholesterol 
biosynthesis since the ER membrane is low in 
cholesterol levels (40). Nevertheless, the effects of 
ZGA on protein modifications, such as 
farnesylation and geranyl-geranylation, have not 
been investigated, so that we cannot dismiss an 
impact of such modifications on the N-
glycosylation pathway at this stage.    
The present study was based on DPM1-deficient 
fibroblasts because this form of CDG shows several 
measurable abnormalities along the biosynthesis of 
N-glycans and GPI-anchored proteins. By contrast, 
PMM2-deficiency that represents the largest group 
of CDG cases (6), does not feature accumulating 
LLO intermediates. Consequently, incomplete 
oligosaccharides on glycoproteins are usually not 
encountered in PMM2-deficiency. However, the 
up-regulation of Dol-P dependent substrates by 
ZGA may be beneficial in normalizing the 
glycosylation disorders caused by deficiency of 
glycosyltransferases catalyzing the attachment of 
the last four Man and three Glc of the LLO 
precursor (7). 
Over the last decade, knockout mouse models for 
PMM2-, MPI- and DPAGT1-deficiency have been 
generated (41-43). These works clearly showed that 
disruption of LLO biosynthesis lead to early 
embryonic lethality. In this context, it would be 
interesting to investigate whether the embryonic 
lethality of the homozygotes could be lagged to a 
later stage of development by treating pregnant 
heterozygous mice with ZGA according to Keller 
(15). In addition, the generation of viable CDG 
mouse models, for instance by introduction of 
selected point mutations, would allow detailed 
analysis of organ specific effects of ZGA in the 
context of inherited N-glycosylation deficiencies. 
This seems to be of particular interest, considering 
that Keller reported an enormous effect of ZGA on 
Dol and Dol-P pools in rat livers, but not in other 
organs such as brain, kidney, intestine or testis (15), 
which was similarly observed in different brain 
cells (44). Subcutaneously administered ZGA 
might preferentially be taken up by mammalian 
livers via a specific hepatic transport mechanism, 
which was likewise proposed in other studies 
(37,38). Considering the frequent impairment of 
liver function in CDG patients (8), the proposed 
hepatic transport system for ZGA would suggest 
that liver N-glycosylation may benefit from 
treatment with the compound. Along this line, it 
would be of interest to address the effect of ZGA 
supplementation in hepatic cell lines, since 
fibroblasts do not represent suitable cell models to 
study glycoprotein secretion. The generation of 
hepatic cell lines with inactivated glycosylation 
genes will represent an opportunity to study the 
regulation of N-glycosylation by ZGA and similar 
compounds. 
In conclusion, this study opens new perspectives in 
developing treatments of glycosylation deficiency 
by showing that manipulation of the dolichol 
biosynthesis pathway, as shown here by ZGA 
administration, represents a valid option. 
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FIGURE LEGENDS 
Figure 1: Statins acting on the sterol biosynthesis pathway. (A) The biosynthetic formation of sterols, 
such as cholesterol, starts from acetyl-CoA and leads via the C15-intermediate farnesyl-PP to its various 
endproducts. The involved enzymes are numbered as follows: (1) acetoacetyl-CoA thiolase, (2) HMG-
CoA synthase, (3) HMG-CoA reductase, (4) mevalonate kinase, (5) phosphomevalonate kinase, (6) 
mevalonate-PP decarboxylase, (7) isopentenyl-PP isomerase, (8) farnesyl-PP synthase, (9) squalene 
synthase, (10) squalene monooxygenase, (11) squalene epoxydase, (12) Dol-P-Man synthase, (13) protein 
farnesyltransferase, (14) geranylgeranyl-PP synthase, (15) protein geranylgeranyltransferase. At the point 
of farnesyl-PP, the pathway diverges to the formation of prenylated proteins, ubiquinone or Dol. The 
polyisoprene Dol-P is incorporated into Dol-P-Man, a key intermediate in protein glycosylation and GPI-
anchor formation. While pravastatin, lovastatin and rosuvastatin lower cellular cholesterol levels by 
inhibiting the pathway at the stage of the HMG-CoA reductase, ZGA achieves this by inhibiting the 
squalene synthase. The chemical structure of ZGA is depicted in (B). 
 
Figure 2: Analysis of cholesterol in healthy control and DPM1-CDG fibroblasts. Steady-state cholesterol 
levels were determined in fibroblasts by GC/MS after organic extraction. Cholesterol levels relative to the 
protein amounts of the extracted mock treated cells are shown as white bars and cholesterol levels of ZGA 
treated fibroblasts are shown as gray bars. Data are represented by mean ± SEM of three independent 
experiments, * p<0.05.  
 
Figure 3: Analysis and quantification of Dol-P levels in mock and ZGA treated control fibroblasts. (A) 
Control cells were grown in the presence of DMSO. Cellular Dol-P were labeled with the fluorophore 9-
anthryldiazomethane and separated by HPLC. The enlarged section in the fluorescent profile highlights 
the separation of the particular Dol-P species. The elution times of mammalian Dol-P standards ranging 
from C90- to C105-Dol-P are indicated below the section. The internal C80-polyprenol-P standard utilized 
for quantification eluted at a retention time of 33.5 min. (B) The separation of Dol-P from ZGA treated 
control fibroblasts is presented in the enlarged section, and the respective Dol-P species were assigned like 
in (A). Quantification was accomplished by comparison with the internal standard hexadecaprenyl-P 
eluting at 34.2 min. (C) The Dol-P levels from four independent HPLC runs were calculated and 
normalized to 107 fibroblasts. White bar represent Dol-P originating from mock treated and gray bars Dol-
P from ZGA treated cells. Data are represented by mean ± SEM of four independent experiments, * 
p<0.05. 
 
Figure 4: Determination of Dol-P-Man levels in mock and ZGA treated fibroblasts. Dol-P-Man was 
metabolically labeled in control and DPM1-CDG fibroblasts by incorporation of [3H]-Man and thereafter 
extracted. The purified lipids were separated by TLC and, on the basis of radiography, the regions 
corresponding to [3H]-Dol-P-Man were scraped and quantified by liquid scintillation. Normalization of 
Dol-P-Man levels relative to the protein amounts of the extracted mock treated cells are shown as white 
bars, while the normalized values of ZGA treated fibroblasts are shown as gray bars. Data are represented 
by mean ± SEM of four independent experiments, * p<0.05. 
 
Figure 5: Cell surface expression of GPI-anchored CD59. (A) Control fibroblasts were stained with a 
FITC conjugated α-human CD59 antibody and analysed by flow cytometry. The fluorescent histogram 
shows unstained cells as gray solid line, mock treated cells as black solid line and ZGA treated cells as 
black dotted line. (B) CD59 expression on DPM1-CDG patient fibroblasts was monitored by flow 
cytometry. Experimental set up and specimen allocations were like for control cells in (A). (C) Control 
(white bars) and DPM1-CDG fibroblasts (gray bars) were incubated with 100 µM ZGA for varying time 
periods and the detected CD59 expressions were normalized to CD59 levels of untreated control 
fibroblasts. (D) Different concentrations of ZGA were administered to control (white bars) or DPM1-CDG 
	 9 
(gray bars) patient fibroblasts for 72 hours. As in (C), the measured CD59 expressions were normalized to 
untreated control cells. Data are represented by mean ± SEM of three independent experiments. 
  
Figure 6: Analysis of ZGA on LLO profiles. Fibroblasts derived from a healthy control (A and B) or a 
DPM1-CDG patient (C and D) were treated for 72 hours either with 100 µM ZGA (B and D) or DMSO as 
control (A and C). Thereafter, the cells were metabolically labeled with [3H]-Man and the LLO were 
extracted and hydrolyzed by mild acid treatment. The released oligosaccharides were purified and 
separated by HPLC. The retention time of standard yeast oligosaccharides ranging from GlcNAc2Man1 
(M1) to GlcNAc2Man9Glc3 (M9G3) are indicated at the top of the profiles. 
 
Figure 7: Protein N-glycosylation in ZGA treated fibroblasts. NLO from control (A and B) and DPM1-
CDG patient fibroblasts (C and D) were separated by HPLC. The protein linked oligosaccharides were 
prepared by PNGaseF endoglycosidase release from metabolically labeled cells previously treated for 72 
hours either with 100 µM ZGA (B and D) or DMSO as control (A and C). The retention times of 
GlcNAc2Man1 (M1) to GlcNAc2Man9Glc3 (M9G3) are marked at the top of the profiles. 
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